Ref-1/APE1 redox signaling affects numerous transcription factors including STAT3, HIF-1α, nuclear factor kappa B (NF-κB), AP-1, p53, and a few others. [13] [14] [15] [16] [17] [18] [19] Ref-1/APE1 redox signaling is a highly regulated process that reduces oxidized cysteine residues in specific transcription factors as part of their transactivation 4, 5, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ( Fig. 1 , Table 1 ). Ref-1/APE1 expression is increased in many tumor types, and that change is associated with increased growth, migration, and drug resistance in tumor cells as well as decreased patient survival. 2, 3, 14, 21, 25, 26 Because of the pathways it affects, Ref-1/APE1 is seen as a critical node in tumor signaling ( Fig. 2 ) and thus is a prime target for anticancer therapy. 2, 3, 19, 21 However, teasing apart Ref-1/APE1's activities to create a specific inhibitor that targets only its endonuclease or redox function is challenging. This has been accomplished with the compound APX3330 (formerly called E3330), which is a specific Ref-1/APE1 redox inhibitor. APX3330 has been extensively characterized as a direct, highly selective inhibitor of Ref-1/APE1 redox activity that does not affect the protein's endonuclease activity in tumors (Section IV; Fig. 6 ). 13, 17, 21, 22, [27] [28] [29] Treatment with APX3330 slows tumor growth and progression, with limited toxicity, in both in vitro and in vivo models. 13, 18, 30, 31 APX3330 is entering clinical trials in mid-2017 and is discussed in Section V of this review.
A number of compounds isolated from natural sources have been proposed as Ref-1/APE1 redox signaling inhibitors, but none have been shown to directly or specifically inhibit Ref-1/APE1 redox signaling. 2, [32] [33] [34] [35] An example of these natural compounds, resveratrol, is typical of the other compounds; its in vivo efficacy is sporadic at best due to widely varying bioavailability and low molecular specificity. [36] [37] [38] [39] [40] [41] Another presumed natural Ref-1/APE1 redox inhibitor, curcumin, has been established as a promiscuous compound, interacting with a variety of molecules to give false positive results in numerous biological assays. [41] [42] [43] These are not specific or viable Ref-1/APE1 redox inhibitors.
Years of research for specific inhibitors of Ref-1/APE1 endonuclease activity similarly have yielded very limited results. An indirect, non-specific inhibitor, methoxyamine, a compound used as a reagent in preparation of 0-methyl oximes, also binds to abasic sites as well as free aldehydes in cells. However, its success in clinical trials has been weak, at best. Direct Ref-1/APE1 endonuclease inhibitors are still in early preclinical stages of development, so their clinical utility is yet to be determined [reviewed in refs. 2, 3] . No direct, Ref-1/APE1-specific endonuclease DNA repair activity inhibitors have moved beyond the hitto-lead stage. 
STAT3
Normal and cancer-induced functions. Signal transducer and activator of transcription-3 (STAT3) drives the transcription of cell growth and survival genes in a variety of cell types. In response to cytokines and growth factors, Janus Kinase (JAK) phosphorylates STAT3, causing STAT3 to dimerize and translocate. [44] [45] [46] Ref-1/ APE1's redox function directly regulates STAT3 DNA binding and transcriptional activity, 13 , 44-46 modulating STAT3's action as a transcription activator.
STAT3 signaling promotes inflammation. Along with other molecules that drive inflammation and tumor growth/spread, STAT3 contributes to tumor progression by upregulating cytokines, growth factors, and matrix metalloproteases. 44, [47] [48] [49] [50] In fact, STAT3 activation is common in tumor tissue, leading to increased growth and invasiveness via transcription of genes involved in mitosis, cell motility, epithelial-mesenchymal transition, extracellular matrix remodeling, and other activities. 48, [51] [52] [53] [54] [55] [56] Hence, both STAT3 signaling and various molecules under STAT3 transcriptional control have been explored as therapeutic targets in cancer. [57] [58] [59] [60] Inhibitors in development. Attempts to develop specific, direct STAT3 inhibitors for clinical purposes have thus far fallen short. [61] [62] [63] The newest lead compound for STAT3 Src homology 2 (SH2) domain inhibition is PG-S3-001, which has apparent selectivity (per a KINOMEscan) and efficacy in both in vitro and in vivo models. 64 Other compounds that can inhibit STAT3's SH2 domain or DNA binding domain have poor specificity for a variety of reasons (reviewed in 62 ). However, other approaches to STAT signaling inhibition continue to be pursued. The JAK inhibitor ruxolitinib blocks JAK signaling, which in turn inhibits STAT3 phosphorylation and activation. Ruxolitinib has been used successfully to treat myelofibrosis and polycythemia, [65] [66] [67] [68] but its efficacy in solid tumors has been minimal at best. 69, 70 Anti-IL-6 therapy has the potential to treat tumors by blocking JAK/STAT signaling. 50 Although the clinical results thus far have been mixed, this approach continues to be studied in a variety of tumor types. [71] [72] [73] Meanwhile, the compounds OPB-31121 and OPB-51602 are being studied as STAT3 inhibitors, 74, 75 but with some reservations. OPB-31121 downregulates JAK2 and the IL-6 receptor gp130, thereby decreasing STAT3 activation via upstream modulators. 76 OPB-51602 has a long halflife, and the accumulation of its active metabolite discourages daily dosing. Results on various tumor types have been mixed. [77] [78] [79] [80] Napabucasin (BBI-608) is being explored as a cancer stem cell inhibitor due to its effects on STAT3 activation as well as on the β-Catenin and Nanog pathways. [81] [82] [83] Still, the search continues for STAT3 inhibitors that are suitable for clinical use. is a multifunctional protein involved in redox signaling and DNA repair. The redox signaling function is responsible for reduction of oxidized cysteine residues in certain transcription factors (TF's), leading to increased transcriptional activity and upregulation of genes involved in cell growth, inflammation, angiogenesis, and other cellular functions. The DNA repair function is responsible for the endonuclease activity in base excision repair, cutting the phosphodiester backbone of DNA at abasic sites created by glycosylases. These cuts allow the abasic sites to be replaced with appropriate nucleotide bases, completing the DNA base excision repair process an upstream JAK2 inhibitor Ruxolitinib, synergistically inhibits proliferation and migration 13 and slows growth in 3D pancreatic cancer spheroids (Fig. 3) . Additionally, inhibition of Ref-1/APE1 redox signaling decreases expression of the STAT3 target survivin, 13 an anti-apoptotic molecule that is a potential target for cancer therapy in its own right. 59, 87, 88 Interestingly, data from a reverse phase protein lysate microarray suggest that JAK2 expression decreases following Ref- 47, [89] [90] [91] [92] [93] [94] [95] [96] Hence, inhibiting Ref-1/APE1 redox signaling alone or in combination with a STAT3 signaling inhibitor could potentially provide a novel approach to cancer therapeutics.
HIF-1
Normal and cancer-induced functions. Hypoxic conditions in all human cells are counteracted by hypoxia inducible factor-1 alpha (HIF-1α) stabilization and subsequent transcription of genes that upregulate cell growth, migration/invasion, and survival. [97] [98] [99] [100] [101] Through HIF activity, cancer cells acquire many malignant properties, including metabolic adaptation and runaway proliferation. 101 Because Ref-1/APE1 redox signaling promotes HIF-1 transactivation, 14, 18 the interplay between HIF-1 and Ref-1/APE1 presents vast opportunity for therapeutic manipulation.
In normoxic conditions, HIF-1α is rapidly degraded following proline hydroxylation and von Hippel-Lindau protein-mediated ubiquitination. But, as oxygen levels decrease, stable HIF-1α levels increase, forming dimers with constitutively expressed HIF-1β (also called aryl hydrocarbon receptor nuclear translocator, ARNT) and binding to hypoxia-response elements in DNA. 100, [102] [103] [104] Inhibitors in development. A drug that inhibits HIF-2α dimerization with ARNT (without affecting HIF-1α) is currently in development. 105 But direct, HIF-1-specific inhibition is not possible yet, despite active interest in targeting HIF-1 signaling in cancer. 103, 106, 107 Several indirect methods for targeting HIF-1α signaling exist, including mTOR inhibition to prevent HIF-1α synthesis, histone deacetylase inhibition to decrease HIF-driven transcription, and unfolded protein response inhibition to decrease transcription that is dependent on HIF cofactors such as XBP1. 103, [108] [109] [110] [111] [112] Notably, FTY720 (fingolimod) has been shown to prevent the stabilization of both HIF-1α isoforms via sphingosine 1-phosphate pathway inhibition. In cell studies and a xenograft model, this led to improved tumor cell killing and vascular remodeling when used in combination with other therapies such as gemcitabine and rapamycin. 113, 114 Similarly, the compound YC-1 downregulated HIF-1α in a MAPK-signaling-dependent manner 115 and inhibited HIF-driven transcription via stimulation of factor inhibiting HIF. 14, 18, 24 Interestingly, HIF-1 cooperates with STAT3 to promote transcription of tumor-promoting factors, [89] [90] [91] so Ref-1/APE1 redox signaling inhibition has the potential to block two transcriptional drivers at once.
Targeting hypoxic cells to inhibit tumor-promoting pathways affected by HIF-mediated transcription is already well established. For instance, VEGF inhibitors such as bevacizumab are used to block tumor-associated angiogenic remodeling; however, acquired resistance is common with those drugs. [117] [118] [119] [120] A major subset of the research into HIF-1 transcriptional targets focuses on pH regulatory systems in hypoxic tumor cells. [121] [122] [123] [124] Carbonic anhydrase IX (CA9) is a transmembrane protein that responds to hypoxia by regulating intracellular pH. CA9 promotes cell survival and invasiveness by acidifying the tumor microenvironment (TME). [124] [125] [126] [127] Because CA9 expression is dependent on HIF-1 activity, it is generally not detectable in normal tissue. In contrast, elevated CA9 expression in cancer tissue is thought to indicate locally advanced tumors with hypoxic regions and a poor chance of treatment response. This positions CA9 as a potential therapeutic target in a variety of tumors. 121, 122, 125, 126, 128, 129 A number of CA9 inhibitors are under development; SLC-0111 is currently in clinical trials. [129] [130] [131] Similarly, bicarbonate transporter inhibition was recently shown to kill hypoxic tumor cells via intracellular acidification; this effect is enhanced with CA9 knockdown. 132 Nuclear factor kappa B Normal and cancer-induced functions. NF-κB is a transcription factor involved in cellular responses to extracellular signals. [133] [134] [135] [136] [137] [138] [139] [140] NF-κB is constitutively inhibited by NF-κB Inhibitor α (IκBα), which is targeted for degradation following phosphorylation by IκB kinase (IKK). That action frees NF-κB to promote the transcription of genes involved in cell proliferation, migration, invasion, and survival. 133, [140] [141] [142] [143] [144] NF-κB signaling contributes to inflammatory responses, which are a major aspect of cancer progression. 49, 133, 135, [145] [146] [147] Inhibitors in development. Although specific inhibitors of NF-κB signaling previously were a hot topic in cancer research, little activity has occurred in this field recently. [148] [149] [150] Its ubiquitous nature has far-reaching, unintended effects on healthy cells when direct inhibition is attempted. 147, 148 In clinical settings, NF-κB 15, 18 Moreover, crosstalk between the STAT3 and NF-κB signaling pathways is well established, involving both feedforward transcription of activating factors and STAT3/NF-κB complexes mediating co-transcription of tumor-promoting genes. 47, [92] [93] [94] [95] [96] This provides further support for Ref-1/APE1 being a master regulator of both enzymes, a pivotal signaling node, and a worthy therapeutic target.
Other transcription factors. AP-1 is an as-yet undruggable transcription factor. Comprising Fos and Jun, AP-1's dimerization drives transcription of proto-oncogenes, making AP-1 an "early response" transcription factor for carcinogenesis.
152-154 AP-1-mediated transcription depends on Ref-1/APE1-mediated reduction of cysteine residues in the DNA-binding regions of both Fos and Jun. 4, 5, 155 Ref-1/APE1 regulates both the transcriptional activity and DNA repair signaling activity of the tumor suppressor p53. 16, 156, 157 Additionally, Ref-1/APE1's redox function negatively regulates transcription factor nuclear factor erythroid-related factor 2 (NRF2). 17 NRF2's cytoprotective functions include regulation of oxidative stress; however, NRF2 also upregulates HMOX-1, a protumorigenic gene responsible for treatment resistance. 158 Combined inhibition of HMOX-1 and Ref-1/APE1's redox activity has been shown to synergistically kill pancreatic cancer cells. Fig. 4 ). This increase is frequently associated with tumorigenesis, cancer aggressiveness, increased angiogenesis, radiotherapeutic and chemotherapeutic resistance, and overall poor prognosis. 21, [159] [160] [161] [162] [163] [165] [166] [167] Conversely, STAT3 activation negatively affects overall survival rates 168 and shortens relapse-free survival (RFS). 169 Ninety five percent of metastatic samples taken from patients who died of castration-resistant prostate cancer were positive for pSTAT3, with the highest expression seen in bone metastases samples. 170 Collectively, this supports the crucial role of pSTAT3 in prostate cancer aggressiveness and progression.
A downstream target of STAT3 is survivin; its increased expression is also associated with prostate cancer aggressiveness. 171 mRNA expression levels of survivin in prostate biopsy tissues show significantly higher survivin expression in cancerous tissue, which correlates with higher-grade cancer and aggressive 172 siRNA knockdown of survivin in prostate cancer cell lines reduces cell proliferation 172 and increases chemosensitivity to the apoptosis-inducing agent cisplatin. 173 The effects of decreased survivin expression extend in vivo. Mice injected subcutaneously with siRNA survivin knockdown cells exhibit significantly smaller tumors compared with controls. 173 Interestingly, Ref-1/APE1 redox-specific inhibitors APX3330 and APX2009 decreased survivin mRNA and protein levels in prostate cancer cells by affecting NF-κB activity. These inhibitors also reduced cell proliferation. In vivo, APX2009 reduced survivin protein levels and cell proliferation. 174 Based on the evidence, both STAT3 and survivin present as prime targets for anti-prostate cancer therapies. However, to date they have been only moderately successful as single-agent therapies. Therefore, the potential combination of inhibiting both Ref-1/APE1 redox function and STAT3/survivin provides an avenue of targeting both the overarching regulator and downstream effector of an anti-apoptotic pathway integral to prostate cancer.
Colon cancer. Colon cancer, the second leading cause of cancer related death in the U.S., 175 exhibits increased levels of cytoplasmic Ref-1/APE1. 176 In liver tumor tissue of metastasized colorectal cancer, increased Ref-1/APE1 expression corresponds to poor patient outcome. 177 In colony-forming assays, siRNA Ref-1/ APE1 knockdown significantly increases the sensitivity of colon cancer cells to ionizing radiation (IR). Furthermore, in vivo subcutaneous xenografts also show reduced tumor growth and radiosensitization following intratumoral Ref-1/APE1 siRNA treatment. 178 The importance of Ref-1/APE1 redox signaling in colon cancer is highlighted by the effects that the Ref-1/APE1 redox inhibitor APX3330 has on colon cancer stem cells (CCSCs). APX3330 significantly reduces CCSC growth in vitro and enhances the cytotoxicity of 5-fluorouracil (5-FU), an anti-metabolite chemotherapeutic. In xenograft mice injected subcutaneously with CCSCs, intratumoral administration of APX3330 increases tumor response to 5-FU delivered intraperitoneally. 179 This indicates that APX3330 could potentiate other colon cancer treatments by inhibiting Ref-1/APE1's crucial redox activity.
Pancreatic cancer. One of the most lethal cancers, pancreatic ductal adenocarcinoma (PDAC) has a 5-year mortality rate of 92% and is characterized by a complex TME, heterogeneity within the tumor, extreme hypoxia, and an inherent ability to metastasize. [180] [181] [182] [183] The regulation of HIF-1α, STAT3, AP-1, and NF-κB by Ref-1/APE1 indicates that inhibition of Ref-1/APE1 redox signaling has potential clinical utility in PDAC.
Ref-1/APE1 levels are elevated in human pancreatic cancer tissue and peri-pancreatic metastasis, and decreasing the expression of Ref-1/APE1 via siRNA in pancreatic cancer cells results in apoptosis, cell cycle arrest, and a decrease in proliferative capacity. 25 Inhibition of Ref-1/APE1 via APX3330 inhibits the proliferation and adhesion of pancreatic cancer cell lines, arrests cell cycle progression, and decreases the transcriptional activation of major transcription factors known to be important in pancreatic cancer progression, survival, metastasis, and response to hypoxia (HIF-1α, NF-κB, STAT3 & AP-1), in addition to blocking tumor growth in vivo in patient-derived models. 13, 18 Within the TME, there are several cell types that contribute to the growth and spread of pancreatic cancer: endothelial cells, pericytes, tumor-associated macrophages, lymphocytes, activated pancreatic stellate cells, and other cancer-associated fibroblasts (CAFs). 182 The role of Ref-1/APE1 in the TME is still under investigation, but there is published evidence 184 that Ref-1/APE1 can block endothelial cell function and suppress tumor-associated macrophages. Preclinical studies show that the Ref-1/APE1 inhibitor APX3330 inhibits growth of pancreatic cancerassociated endothelial and endothelial progenitor cells. 185 Additional studies demonstrate that APX3330 can reduce tumor endothelial VEGF secretion, blocking a potentially critical angiogenic ligand-receptor interaction in the TME. 185 Based on these data and the regulation of key transcription factors implicated in PDAC, PDAC is one of the indications for APX3330 in clinical trials. Some studies show increased expression primarily in the cytoplasm. 186, 187 In those studies, cytoplasmic localization of Ref-1/APE1 correlates with ovarian tumor progression. Additionally, patients with advanced (stage III/IV) cancer have significantly higher Ref-1/APE1 expression and lower overall survival rates than stage I/II patients. 188 Patients with increased cytoplasmic Ref-1/ APE1 are also more resistant to platinating chemotherapeutics. 189 A different study observed increased Ref-1/APE1 nuclear expression, again with greater increases in stage III/IV compared to stage I/II patients. 190 In other studies, both nuclear and cytoplasmic Ref-1/APE1 expression were increased 189, 191 -but no correlation was observed between Ref-1/APE1 expression and the cancer stage. 203 and cisplatindocetaxel-gemcitabine treatment, 81 with longer time to progression and overall survival.
Evidence exists that reducing Ref-1/APE1 increases the efficacy of other anticancer treatments in NSCLC. Decreasing Ref-1/APE1 levels in A549 cells in vitro and in vivo increases the effectiveness of photodynamic therapy. 204 Ref-1/APE1 knockdown with shRNA enhances the anti-tumor activity of oxymatrine, an alkaloid compound that inhibits proliferation of A549 cells. 205 Collectively, this demonstrates that Ref-1/APE1 plays a vital role in NSCLC progression, and targeting it might lead to better patient outcomes when combined with various chemotherapeutic treatments.
Malignant peripheral nerve sheath tumors (MPNST).
MPNST is an uncommon neural-origin cancer that can be deadly. Despite much research to date, existing chemotherapeutic agents have not been successful in MPNST treatment. 206 Recent research implicates Ref-1/APE1 redox targets HIF-1α and particularly STAT3 in driving MPNST.
Phosphorylated STAT3 expression may indicate aggressive disease at disease onset. A tissue microarray showed STAT3 expression in primary MPNST was associated with worse diseasespecific overall survival and event-free survival. 207 In a mouse model of EGFR overexpression, both a JAK/STAT3 inhibitor and STAT3 knockdown by shRNA prevented tumor formation. 208 In another study, inhibition of STAT3 activation in four MPNST lines resulted in decreased wound healing, cell migration, invasion, and tumor formation. It also reduced HIF-1α expression. Independent shRNA-mediated HIF-1α knockdown also decreased wound healing, cell migration, invasion, and tumor formation, showing that the STAT3/HIF-1 α signaling pathway is responsible for tumorigenesis in MPNST. 90 Furthermore, STAT3's downstream target survivin is amplified in MPNSTs. 209 Survivin is highly expressed in MPNST tissue samples. Survivin knockdown via siRNA decreases cell growth, inhibits cell cycle progression and increases apoptosis. Additionally, survivin inhibitor YM155 represses MPNST xenograft growth and metastasis in vivo. and its relationship to all-trans retinoic acid (ATRA, or RA) and retinoic acid receptor (RAR) transcription factors. RAR alpha binds to its DNA binding site retinoic acid response element (RARE) in a redox-dependent fashion. Studies by Fishel et al 27 demonstrate that RAR-RARE binding is blocked through Ref-1/APE1 redox inhibition using APX3330. Additionally, the addition of APX3330 to ATRA increases apoptosis and cellular differentiation of APL cells by threefold. These results indicate the potential of using APX3330 in combination treatment with ATRA. This could accomplish two things; first, a new treatment combination for leukemias where ATRA is used, and second, a reduction in the ATRA dose while maintaining similar or increased therapeutic effect. This latter point is important, as one should be able to avoid the toxicity of RA differentiation syndrome by being able to increase RA-induced promyeloblast differentiation, but with lower amounts of RA. Reducing the dose of RA has important clinical implications and could help to eliminate some of the undesirable side effects of this therapy. 211, 212 RA administration can cause differentiation syndrome in 25% of patients. (Fig. 4) . Elevated Ref-1/APE1 has been implicated in age-related cataracts.
Ref 29, 217 Similarly, APX3330 treatment reduced proliferation, migration and angiogenesis in CECs in primate cells in vitro and had an additive effect when combined with bevacizumab. 219 RPEs stressed using oxidized low-density lipoproteins were rescued from proliferation decline and senescence by APX3330. 218 In adult human RPE cell lines, APX3330 reduced the transcriptional activity of NF-κB, a key factor associated with inflammation in angiogenesis. 218, 219 It also blocked activation of HIF-1α and reduced the expression of its downstream target VEGF. 219 VEGF expression via NF-κB and HIF-1α is primarily responsible for choroidal neovascularization (CNV), a characteristic of neovascular age-related macular degeneration (AMD), also known as wet AMD.
When very low density lipoprotein receptor knockout mice are treated with a single intravitreal injection of APX3330, CNV is reduced.
217 APX3330 also shows anti-angiogenic effects in mice with laser-induced CNV. 219 Angiogenesis is also a prime component of other retinal diseases, including retinopathy of prematurity (ROP) and diabetic retinopathy (DR). Ref-1/APE1's redox ability to modulate angiogenesis makes it worth investigating in those diseases. Interestingly, both HIF-1α and VEGF are increased in ROP and DR. Retinal neovascularization, a marker of ROP and DR, is markedly reduced in mice with ischemic retinopathy when treated with siRNA targeting HIF-1α or VEGF. 220 However, the difficulties in creating druggable targets for HIF-1α have already been discussed. Additionally, ocular anti-VEGF therapies are not always effective and may lead to unwanted side effects. 221 237 These findings highlight the wide range of diseases affected by Ref-1/APE1, indicating that it is a promising target for treating and managing numerous diseases.
IDENTIFICATION OF ADDITIONAL PATHWAYS FOR COMBINATORIAL DRUG APPROACH
A proposed factor in the limited success of molecular therapies has been the heterogeneity found in tumor samples, especially aggressive ones such as pancreatic tumors or glioblastomas. This underscores the need for strategies that target nodal proteins capable of affecting multiple pathways, such as Ref-1/APE1. 180, 181, 238 The evaluation of novel targets including Ref-1/APE1 and rationally designed combination therapy, including correlative biomarker research, is critical in cancer because therapeutic options for some cancer patients remain limited.
To elucidate synthetic lethal pairs of chemotherapeutic agents, two general approaches are utilized. They include rational, hypothesis-driven combinations based on the mechanism of action of the compounds as well as application of "big data" that reveal specific gene expression profiles or proteomic signatures that would render cancer cells vulnerable when used in combination. To that end, this section focuses on combination therapy that involves Ref-1/APE1 modulation that results in even greater enhancement than either agent alone; synergistic effects.
Many studies have investigated the potentiation of DNAdamaging agents in combination with Ref-1/APE1 inhibition [239] [240] [241] ). Presumably the predominant mechanism of potentiation in these studies was due to blockade of Ref-1/APE1's DNA repair function, which led to cellular inability to respond to the DNA damage caused by the chemotherapeutic agent. In this review, we focus on published studies of inhibition of Ref should create a synthetic lethality, dramatically enhancing cell death compared to their effect when administered alone.
Using this approach, our group discovered that impinging upon STAT3 signaling in combination with Ref-1/APE1 signaling dramatically affects the viability and migratory ability of pancreatic cancer cell lines (Fig. 3 and ref. 13) .
Several studies of different cancers support the notion that combination therapy involving inhibition of Ref-1/APE1 in tumorpromoting processes such as hypoxia or angiogenesis is efficacious. In an osteosarcoma model characterized by hypoxia and angiogenesis, inhibition of Ref-1/APE1 in combination with endostatin demonstrates in vivo efficacy with decreases in VEGF expression and microvessel density. 14 Using pancreatic 3D co-culture models, tumor spheroid area is reduced after dual targeting with Ref-1/APE1 and CA9 (Fig. 2) . The mechanism of enhancement is believed to be due to an increase in pH and blockade of the tumor's ability to adapt to hypoxic conditions perpetuated through simultaneous CA9 and Ref-1/APE1 blockade.
Finally, studies comparing doxorubicin-sensitive vs. doxorubicin-resistant colon cancer cells demonstrate that hypoxia enhances the expression of Pgp (P-glycoprotein) and BCRP (breast cancer resistance protein)-and that the addition of APX3330 to doxorubicin under hypoxic conditions can attenuate HIF activity significantly, blocking the upregulation of Pgp and BCRP. This decrease in Pgp and BCRP expression may play a role in the observed increase in doxorubicin accumulation, especially in the parental cells. 243 The results suggest that, when blockade of Ref-1/ APE1's redox function blockades HIF signaling, colon cancer cells' response to doxorubicin may be enhanced. A caveat to these studies is that hypoxia was chemically induced using cobalt chloride rather than lowering oxygen levels in the cells, and only Pgp seemed to be regulated at the transcriptional level by hypoxia and doxorubicin treatment. This would suggest that additional mechanisms of drug resistance are at play.
A recent study by Ren et al. 244 sought to sensitize NSCLC cell lines to cisplatin by sequential use of AT-101 (gossypol) with cisplatin. AT-101 exerts its anti-tumor effects in many ways: it is a BH3-mimetic and also has been shown to inhibit Ref-1/APE1's DNA repair and redox activities. Blockade of the anti-apoptotic proteins Bcl-2 and Bcl-XL through Ref-1/APE1's redox inhibition of STAT3 activity contributes to the enhanced cell killing and tumor growth seen in this combination. 244 Furthermore, in NSCLC cell line A549, siRNA inhibition of Ref-1/APE1 expression significantly sensitizes A549 cells to cisplatin and increased cell apoptosis. 202 Both of these studies point to Ref-1/APE1 function as critical in the cells' response to cisplatin, especially in apoptosis signaling through STAT3.
In contrast, a recent study in breast cancer cell lines that were exposed to cisplatin in combination with inhibitors of either Ref-1/ APE1 repair or Ref-1/APE1 redox activity, cisplatin resistance increased. 245 The authors conjecture that a concurrent downregulation of mismatch repair proteins (MSH2, MSH6, MLH1, and ERCC1) may explain why those results differ from the other studies that demonstrate a greater response to cisplatin when Ref-1/APE1 is inhibited concurrently. In the pursuit of personalized medicine, these preclinical studies demonstrate the importance of elucidating cell-specific signaling following chemotherapy as well as the crosstalk between DNA repair pathways that occurs following DNA damaging agents. These factors will need to be considered as new treatment combinations are proposed, such as considering the addition of a Ref-1/APE1 inhibitor to a cisplatin regimen. effective combination treatments to utilize in cancer treatment settings. 247, 248 The goal is to accelerate the selection of likely synthetic lethal targets, particularly for aggressive cancers that have few treatment options.
For example, historically in pancreatic cancer, new targeted agents would be paired with the standard-of-care agent, gemcitabine. But adding selective inhibitors of multiple cancerrelated pathways to gemcitabine either did not extend survival significantly or although statistically significant did not extend the 5-year survival rate. 249 In today's age of omics, "big data" can be used to predict synthetic lethality and effective drug combinations rather than a shotgun approach. Much is yet to be learned regarding which clinical agents will pair most effectively with Ref-1/APE1 redox or repair inhibitors; however, studies are ongoing to determine whether this approach will yield drug combinations that are synthetically lethal to cancer cells.
REF-1/APE1 DNA REPAIR AND CIPN; INDIRECT IMPACT LINKING THROUGH ALTERING REDOX FUNCTION
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent dose-limiting toxicities of anticancer therapy. Up to 90% of cancer patients experience CIPN at some point during or after anticancer treatment. 251 Indeed, anticancer drugs used for the six most common malignancies pose a substantial risk for CIPN. These drugs include, but are not limited to platinum agents, taxanes, vinca alkaloids, proteasome inhibitors, immunomodulators and even new, targeted therapeutic agents. There are currently no approved treatments to prevent or treat CIPN, thus the neurotoxicity can be dose-limiting for some patients. 252 Platinum drugs, particularly cisplatin and oxaliplatin, are an important component of numerous standard-of-care treatment regimens for pediatric and adult cancers; for example, oxaliplatin is a part of the FOLFIRINOX and FOLFOX protocols.
CIPN can persist after treatment is completed. Up to 40% of cancer patients continue to struggle with CIPN five years after treatment ends 252 -and 10% remain symptomatic after more than 20 years. Thus, CIPN directly affects cancer survivorship, quality of life, and may limit future treatment options if cancer recurs. 252 In previous studies using an experimental model of cultured sensory neurons, we established a causal relationship between CIPN and DNA damage and repair. 31, 106, 253, 254 We demonstrated that reducing the activity of the DNA BER pathway by reducing expression of Ref-1/APE1 increased the neurotoxicity produced by anticancer treatment, whereas, augmenting the expression of Ref-1/APE1 lessened the neurotoxicity. 31, [255] [256] [257] Additionally, we demonstrated that Ref-1/APE1's DNA repair function-not the redox signaling function-is crucial for sensory neuron survival and function. 31 We also demonstrated that the small-molecule redox inhibitor APX3330 protects sensory neurons from oxidative DNA damage caused by IR, 31 cisplatin, 254 and oxaliplatin (Fig. 5) . This raises the question: how does a Ref-1/APE1 redox-specific inhibitor affect DNA repair activity? Although APX3330 is a targeted inhibitor of Ref-1/APE1's redox function, it appears that, in the setting of sensory neurons, it can also enhance the protein's DNA repair (AP endonuclease) activity (Fig. 6 ). Although this seems counterintuitive, on closer inspection it is not so unexpected. APX3330 causes the protein to unfold over time. 21, 22, 28 This unfolding primarily alters the amino end of Ref-1/APE1, affecting its interactions with downstream transcription factor targets by perturbing the equilibrium of the protein's folded/unfolded states and facilitating repair activity. 21, 28, 258 254 -which is not observed in tumor cells. 29, 258, 259 As discussed in previous paragraphs, we found that APX3330 protected sensory neurons from DNA damage and reactive oxygen species (ROS) production induced by agents such as IR, cisplatin and oxaliplatin. 31, 254 A critical property of any putative therapeutic for neurotoxicity is that it will not compromise the anticancer function of the treatment (s) administered. Importantly, the enhancement of DNA repair activity by APX3330 was not observed in mitotic cells. 22, 258, 260 We have shown that APX3330 negatively affects the growth and/ or survival of tumor cell lines, patient-derived cell lines, and tumors in animal models. 13, 17, 18, 25, 27, 29 Therefore, it is possible that APX3330 could protect postmitotic cells without altering the effects of anticancer drugs on tumor cells (Fig. 6) . Additionally, APX3330 does not affect cisplatin or oxaliplatin's tumor-killing efficacy in vivo, yet it protects DRG neurons from oxidative DNA damage (data unpublished). If further translational research further bears out these findings, APX3330 could be offered as a neuroprotective mechanism in humans, facilitating BER repair of oxidative DNA damage and protecting sensory neurons. In healthy cells, it appears that the DNA repair functionnot the redox function of Ref-1/APE1-is necessary for sensory neuronal survival/function. That is opposite from tumor cells. Collectively, these data support the notion that APX3330 can be neuroprotective against cancer therapy without compromising treatment.
PRECISION ONCOLOGY-BIOMARKERS
Biomarkers are at the frontier of precision oncology. Ideally, they provide diagnostic, prognostic, or pharmacologic information to inform patient care. 261 Biomarkers may be genetic variants (polymorphisms), abnormal protein production/expression, or protein dysfunction unique to cancers. 261, 262 The premise of pursuing Ref-1/APE1 as a potential biomarker is based on its contributions to both disease suppression and therapeutic agent resistance. 261 Variants in DNA repair pathways are common; however, they may not alter protein synthesis. 261 For example, (also see Table 2 , Fig. 4) . Tumorigenesis, cancer aggressiveness, increased angiogenesis, radiotherapeutic and chemotherapeutic resistance, and overall poor prognosis are all associated with increased Ref-1/APE1 levels. 21, [159] [160] [161] [162] [163] These cancers include prostate, colon, pancreatic, ovarian, non-small cell lung carcinoma, leukemias, MPNST, brain tumors, osteosarcoma, rhabdomyosarcoma, endothelial cell tumor, breast cancer (including triple-negative), hepatocellular carcinoma (HCC), head and neck, bladder, multiple myeloma, pediatric epdndymoma and retinoblastoma (Table 2) . 3, 239, 261, 265, 267 Additionally, low levels of Ref-1/APE1 appear to predict sensitivity to platinating agents for several cancers, especially NSCLC. 81, 263, 268 Furthermore, a drop in serum Ref-1/APE1 levels pre-vs. post-treatment can indicate better overall survival or longer progression-free survival in some cancers, particularly NSCLC. 81 Low Ref-1/APE1 levels confer radiosensitivity in pancreatic, colorectal, and cervical cancer cell lines. 178, 194, 269, 270 Human HCC has elevated Ref-1/APE1 levels suggesting that over-expression in HCC correlates with cancer aggressiveness and indicates Ref-1/APE1 to be a promising marker. 160 Additionally, increased Ref-1/APE1 cytoplasmic expression is a predictor of survival for HCC. 271 Ref-1/APE1 normally localizes to the nucleus, with a much smaller but relevant localization to the mitochondria. A shift to greater cytoplasmic localization is present in some cancers; mounting evidence indicates that may be prognostic. 160, 191, 197, 271, 272 The reason for this abnormal subcellular trafficking is yet unknown; perhaps post-translational modifications drive the protein's redistribution or a general increase in Ref-1/APE1 levels result in a net cytoplasmic increase. APE1's distribution pattern varies by cancer type and stage, the tumor's genetic composition and microenvironment, and further work needs to be done in this area.
Currently the most promising work with Ref-1/APE1 as a biomarker is with regard to bladder cancer. This includes the development of an ELISA based Ref-1/APE1 assay. A 2016 study by Choi showed that an increase in Ref-1/APE1 expression at a cutoff of 0.376 ng/100μl was 82% sensitive and 80% specific for detecting bladder cancer in urine. 273 A smaller study from 2015 showed higher sensitivity (90%) but lower specificity (59%) for utilizing Ref-1/APE1 in serum to detect bladder cancer. The drug has not been approved in Japan nor the US which necessitates new oncology phase 1 trials. APX3330 is extremely well-tolerated at dose levels consistent with development as a cancer agent. It has IND and IRB approval. Eisai preclinical and clinical data demonstrates a safety profile that supports development of APX3330 for the treatment of various cancers. This includes (taken from the filed IND): (a) 13 week dog and rat studies with unremarkable safety findings, (b) Phase 1 (75 Japanese subjects) with single or multiple doses and Phase 2 (>350 Japanese subjects with hepatitis B or C; acute severe hepatitis or alcoholic hepatitis) with unremarkable safety findings, (c) No acute toxicity seen on neurologic, cardiovascular or pulmonary function, (d) Linear pharmacokinetics of APX3330 with little accumulation, (e) Absorption, distribution, metabolism and excretion of APX3330 understood, and (f) In Phase 2 trials, APX3330 was detected in serum at concentrations up to 147 μM; levels well above that required for anti-tumor effect in our models of pancreatic cancer. Eisai also concluded there were improvements in transaminase levels in patients with hepatitis B and C. APX3330 is well absorbed orally with a bioavailability of ≥60%. All of this data greatly de-risks the drug and due to its lack of toxicity profile, it will likely be easy to combine with other agents.
The phase 1, multicenter, open-label, dose-escalation oncology study will commence in 2017, with the goal of identifying a recommended phase 2 study dose to be used for subsequent development of the agent. The study population will include patients with recurrent or advanced cancer (i.e., solid tumors) for whom standard therapy offers no curative potential. APX3330 will be supplied as orally administered tablets and patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle.
Additional study endpoints include pharmacokinetic and pharmacodynamic (PD) characterization of APX3330, the latter involving analysis of blood and tissue obtained from participants, including the following: 253 A number of novel analogs have been synthesized based on structure-activity relationship. Changes include alterations of the dimethoxybenzoquinone with a napthoquinone ring, modification of the carboxylic acid, carbon chain on the double bond shortened, and substitution of the methyl group on the ring structure with hydrogen or various halogens. 29, 253, 259, 260 APX3330 exists as a charged molecule at physiological pH; the addition of amide derivatives of carboxylic acid altered APX3330's physical properties. Also, the lipophilic carbon chain was shortened on the double bond, making the new compounds less lipophilic 253 [Patent 9,089,605]. These changes resulted in new compounds that exhibited greater potency than APX3330 during in vitro testing. 253 The current compounds attack Ref-1/APE1 in a highly selective and specific manner, causing local unfolding of the protein and inhibiting its redox signaling function. 12, 21, 22, 28 Identification of additional compounds outside of the chemical space of APX3330 and its analogs is not an easy task and is not readily amenable to high-throughput screening. Screening for molecules that block protein-protein interactions and, in this case, recognize an alternative redox-active conformation of Ref-1/APE1, are intrinsically complicated to find. One must rule out extraneous nonspecific hits and target Ref-1/APE1 without unwanted toxicities or promiscuous activity. 14, 17, 18, 180 STR analysis (CellCheck with IDEXX BioResearch) was used to confirm the identity of the cells and that they were mycoplasma-free. Cells were passaged up to 10 times before new stocks were thawed. 3-dimensional tumor spheroids were cultured in DMEM containing 3% reduced growth factor matrigel (BD Biosciences) and 5% FBS as previously described. 14, 64, 275 Cells were stably transduced as follows: tumor cells with TdTomato (red), CAF cells with EGFP (green). 64, 180 3D cultures were treated on Days 4 and 8 after plating with inhibitors as indicated and analyzed using Thermo ArrayScan high-content imaging system on Day 12 after plating. 276 Western blot analysis. Western blots were performed as previously described 14, 17, 18, 25, 253 with antibodies for Ref-1/APE1 (Novus Biologicals; Littleton, CO), phospho-STAT3 & total-STAT3 (Cell Signaling; Danvers, MA), phospho-histone H2AX (EMD Millipore; Billerica, MA), and Vinculin (Sigma; St. Louis, MO). All samples were processed and run in parallel.
THE FUTURE
Inhibitors. APX3330 was prepared and used as previously described. 14, 27, 28 Ruxolitinib was dissolved in DMSO prior to dilution in media and use at the concentrations specified (Santa Cruz; Dallas, Texas).
In vivo CIPN studies in tumor bearing mice. The treatment protocol is presented in Fig. 6C . IMR32 Neuroblastoma cells 253 were implanted subcutaneously into the right flanks of 6-wk old male NSG mice and allowed to proliferate until tumor volumes ≥ 150 mm 3 . Mice were then randomized for treatment with cisplatin ± E3330 treatment. Cisplatin and E3330 were administered concurrently for 3 weeks (Day 0-Day 17) and endpoints of neuronal toxicity were assessed within the DRG of mice at several time points following the last dose of cisplatin. pH2A.X immunoreactivity was performed on isolated DRG neurons as previously described 253, 254 and shown in Fig. 6D . Quantification of pH2A.X immunoreactivity after normalization to vinculin was performed as previously described 253, 254 (Fig. 6E ). An asterisk indicates statistical significance between D18 and D24 as determined by a one-way ANOVA with Tukey's posttest with p < 0.05. A cross indicates statistical significance between Veh/Veh group and the Veh/Cis group, as determined by a two-way ANOVA with Bonferroni's posttest with p < 0.05. Mouse monoclonal anti-phospho-H2A histone X and vinculin antibodies were from EMD Millipore (Billerica, MA). Chemiluminescence secondary antibodies were from Roche Diagnostics (Indianapolis, IN). Ref-1 antibody was from Novus Biologicals, CO. 253, 254 Cisplatin was purchased from Sigma-Aldrich (St. Paul, MN). Neuroblastoma cells, IMR32, were obtained from American Type Culture Collection (Manassas, VA) and grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cell line identity was confirmed by DNA fingerprint analysis (IDEXX BioResearch, Columbia, MO) for species and baseline short-tandem repeat analysis testing. All cell lines were 100% human and a nine-marker short tandem repeat analysis is on file. They were also confirmed to be mycoplasma free. All samples were processed and run in parallel.
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